Jane E. Craig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jane E. Craig has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Amit Budhraja
St Jude Childrens Res Hosp, Dept Cellular & Mol Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA
1 shared publication- Fatima Rivas
Department of Chemistry, Louisiana State University, 133 Choppin Hall, Baton Rouge, LA 70803, USA
1 shared publication Gamze B. Bulut
Department of Cell Biology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, 75390, USA
1 shared publicationJamshid Temirov
Department of Cell and Molecular Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105, USA
1 shared publicationJohn Bollinger
St Jude Childrens Res Hosp, Dept Struct Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA
1 shared publicationJonathan A. Low
Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, Tennessee, 38105, USA
1 shared publication
Latest Publications
- Open Access
- 20 October 2020
- Published by Springer Nature in Cell Death Discovery
- Vol. 6 (1) , 1-13
MEKK3-MEK5-ERK5 signaling promotes mitochondrial degradation
Mitochondria are vital organelles that coordinate cellular energy homeostasis and have important roles in cell death. Therefore, the removal of damaged or excessive mitochondria is critical for maintaining proper cellular function. The PINK1-Parkin pathway removes acutely damaged mitochondria through a well-characterized mitophagy pathway, but basal mitochondrial turnover occurs via distinct and less well-understood mechanisms. Here we report that the MEKK3-MEK5-ERK5 kinase cascade is required for mitochondrial degradation in the absence of exogenous damage. We demonstrate that genetic or pharmacological inhibition of the MEKK3-MEK5-ERK5 pathway increases mitochondrial content by reducing lysosome-mediated degradation of mitochondria under basal conditions. We show that the MEKK3-MEK5-ERK5 pathway plays a selective role in basal mitochondrial degradation but is not required for non-selective bulk autophagy, damage-induced mitophagy, or restraint of mitochondrial biogenesis. This illuminates the MEKK3-MEK5-ERK5 pathway as a positive regulator of mitochondrial degradation that acts independently of exogenous mitochondrial stressors.
- 20 October 2020
- Published by Springer Nature in Cell Death Discovery
- Vol. 6 (1) , 1-13
Open AccessMEKK3-MEK5-ERK5 signaling promotes mitochondrial degradation
Mitochondria are vital organelles that coordinate cellular energy homeostasis and have important roles in cell death. Therefore, the removal of damaged or excessive mitochondria is critical for maintaining proper cellular function. The PINK1-Parkin pathway removes acutely damaged mitochondria through a well-characterized mitophagy pathway, but basal mitochondrial turnover occurs via distinct and less well-understood mechanisms. Here we report that the MEKK3-MEK5-ERK5 kinase cascade is required for mitochondrial degradation in the absence of exogenous damage. We demonstrate that genetic or pharmacological inhibition of the MEKK3-MEK5-ERK5 pathway increases mitochondrial content by reducing lysosome-mediated degradation of mitochondria under basal conditions. We show that the MEKK3-MEK5-ERK5 pathway plays a selective role in basal mitochondrial degradation but is not required for non-selective bulk autophagy, damage-induced mitophagy, or restraint of mitochondrial biogenesis. This illuminates the MEKK3-MEK5-ERK5 pathway as a positive regulator of mitochondrial degradation that acts independently of exogenous mitochondrial stressors.
- 14 May 2019
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 82 (5) , 1301-1311
Studies of Jatrogossone A as a Reactive Oxygen Species Inducer in Cancer Cellular Models
Natural products continue to provide a platform to study biological systems. A bioguided study of cancer cell models led us to a new member of the jatrophane natural products from Jatropha gossypiifolia, which was independently identified and characterized as jatrogossone A (1). Purification and structure elucidation was performed by column chromatography and high-performance liquid chromatography–mass spectrometry and NMR techniques, and the structure was confirmed via X-ray crystallography. The unique molecular scaffold of jatrogossone A prompted an evaluation of its mode of action. Cytotoxicity assays demonstrated that jatrogossone A displays selective antiproliferative activity against cancer cell models in the low micromolar range with a therapeutic window. Jatrogossone A (1) affects mitochondrial membrane potential (ΔΨm) in a time- and dose-dependent manner. This natural product induces radical oxygen species (ROS) selectively in cancer cellular models, with minimal ROS induction in noncancerous cells. Compound 1 induces ROS in the mitochondria, as determined by colocalization studies, and it induces mitophagy. It promotes also in vitro cell death by causing cell arrest at the G2/M stage, caspase (3/7) activation, and PARP-1 cleavage. The combined findings provide a potential mechanism by which 1 relies on upregulation of mitochondrial ROS to potentiate cytotoxic effects through intracellular signaling.
- 14 May 2019
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 82 (5) , 1301-1311
Studies of Jatrogossone A as a Reactive Oxygen Species Inducer in Cancer Cellular Models
Natural products continue to provide a platform to study biological systems. A bioguided study of cancer cell models led us to a new member of the jatrophane natural products from Jatropha gossypiifolia, which was independently identified and characterized as jatrogossone A (1). Purification and structure elucidation was performed by column chromatography and high-performance liquid chromatography–mass spectrometry and NMR techniques, and the structure was confirmed via X-ray crystallography. The unique molecular scaffold of jatrogossone A prompted an evaluation of its mode of action. Cytotoxicity assays demonstrated that jatrogossone A displays selective antiproliferative activity against cancer cell models in the low micromolar range with a therapeutic window. Jatrogossone A (1) affects mitochondrial membrane potential (ΔΨm) in a time- and dose-dependent manner. This natural product induces radical oxygen species (ROS) selectively in cancer cellular models, with minimal ROS induction in noncancerous cells. Compound 1 induces ROS in the mitochondria, as determined by colocalization studies, and it induces mitophagy. It promotes also in vitro cell death by causing cell arrest at the G2/M stage, caspase (3/7) activation, and PARP-1 cleavage. The combined findings provide a potential mechanism by which 1 relies on upregulation of mitochondrial ROS to potentiate cytotoxic effects through intracellular signaling.